Bristol-Myers Squibb (BMY) Tops Q2 EPS by 3c; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Bristol-Myers Squibb Reports Second Quarter Financial Results
July 28, 2016 6:59 AM EDTIncreases Second Quarter Revenues 17% to $4.9 Billion Posts Second Quarter GAAP and Non-GAAP EPS of $0.69 Achieves Important Regulatory Milestones in Immuno-Oncology Opdivo + Yervoy Regimen Approved in Europe for Metastatic Melanoma Opdivo Approved in the U.S. for the Treatment of Classical Hodgkin Lymphoma Opdivo Granted Breakthrough Therapy Designation for Advanced Form of Bladder Cancer Empliciti Approved in Europe for Combination Treatment for Multiple Myeloma... More
